## Ayse Sahaboglu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8732242/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Spectral Domain Optical Coherence Tomography in Mouse Models of Retinal Degeneration. , 2009, 50, 5888.		193
2	ldentification of a Common Non-Apoptotic Cell Death Mechanism in Hereditary Retinal Degeneration. PLoS ONE, 2014, 9, e112142.	2.5	191
3	Excessive HDAC activation is critical for neurodegeneration in the rd1 mouse. Cell Death and Disease, 2010, 1, e24-e24.	6.3	100
4	Calpain and PARP Activation during Photoreceptor Cell Death in P23H and S334ter Rhodopsin Mutant Rats. PLoS ONE, 2011, 6, e22181.	2.5	94
5	Combination of cCMP analogue and drug delivery system provides functional protection in hereditary retinal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2997-E3006.	7.1	90
6	Protective effects of various antioxidants during ischemia-reperfusion in the rat retina. Graefe's Archive for Clinical and Experimental Ophthalmology, 2006, 244, 627-633.	1.9	74
7	Inhibition of Mitochondrial Pyruvate Transport by Zaprinast Causes Massive Accumulation of Aspartate at the Expense of Glutamate in the Retina. Journal of Biological Chemistry, 2013, 288, 36129-36140.	3.4	72
8	PARP1 Gene Knock-Out Increases Resistance to Retinal Degeneration without Affecting Retinal Function. PLoS ONE, 2010, 5, e15495.	2.5	71
9	Neuroprotective Strategies for the Treatment of Inherited Photoreceptor Degeneration. Current Molecular Medicine, 2012, 12, 598-612.	1.3	68
10	Retinitis pigmentosa: rapid neurodegeneration is governed by slow cell death mechanisms. Cell Death and Disease, 2013, 4, e488-e488.	6.3	67
11	Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration. Scientific Reports, 2016, 6, 39537.	3.3	45
12	Retinitis pigmentosa: impact of differentPde6apoint mutations on the disease phenotype. Human Molecular Genetics, 2015, 24, 5486-5499.	2.9	41
13	HDAC inhibition in the <i>cpfl1</i> mouse protects degenerating cone photoreceptors <i>in vivo</i> . Human Molecular Genetics, 2016, 25, ddw275.	2.9	39
14	Organotypic retinal explant cultures as in vitro alternative for diabetic retinopathy studies. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 459-464.	1,5	29
15	Poly ADP ribosylation and extracellular vesicle activity in rod photoreceptor degeneration. Scientific Reports, 2019, 9, 3758.	3.3	25
16	Temporal progression of PARP activity in the Prph2 mutant rd2 mouse: Neuroprotective effects of the PARP inhibitor PJ34. PLoS ONE, 2017, 12, e0181374.	2.5	23
17	Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration. Cellular and Molecular Life Sciences, 2020, 77, 2199-2216.	5.4	20
18	Knockout of PARG110 confers resistance to cGMP-induced toxicity in mammalian photoreceptors. Cell Death and Disease, 2014, 5, e1234-e1234.	6.3	13

Ayse Sahaboglu

#	Article	IF	CITATIONS
19	Deletion of myosin VI causes slow retinal optic neuropathy and age-related macular degeneration (AMD)-relevant retinal phenotype. Cellular and Molecular Life Sciences, 2015, 72, 3953-3969.	5.4	10
20	Release of Retinal Extracellular Vesicles in aÂModel of Retinitis Pigmentosa. Advances in Experimental Medicine and Biology, 2019, 1185, 431-436.	1.6	8
21	Expression of Poly(ADP-Ribose) Glycohydrolase in Wild-Type and PARG-110 Knock-Out Retina. Advances in Experimental Medicine and Biology, 2014, 801, 463-469.	1.6	2